The hemoglobinopathies encompass all genetic diseases of hemoglobin. They fall into two main groups: thalassemia syndromes and structural hemoglobin variants (abnormal hemoglobins). α and β thalassemia are the main types of thalassemia; the main structural hemoglobin variants are HbS, HbE, and HbC. There are many subtypes and combined types in each group. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Stem-cell transplantation is the preferred treatment for severe forms of thalassemia. Supportive, rather than curative, treatment consists of periodic blood transfusions for life combined with iron chelation. Drugs to treat the symptoms of sickle-cell disease include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. Blood transfusions should be given only when strictly indicated. More than 90% of patients currently survive into adulthood. Optimally treated patients have a projected life span of 50 to 60 years. With approximately 7% of the worldwide population being carriers, hemoglobinopathies are the most common monogenic diseases and one of the world’s major health problems. They were originally found mainly in the Mediterranean area and large parts of Asia and Africa. International migration has spread them from those areas all over the world. In many parts of Europe today, hemoglobin (Hb) defects are classified as endemic diseases.

Market Dynamics

Increasing launches of new products and mergers and acquisitions by key market players are expected to drive the global hemoglobinopathy treatment drugs market growth. For instance, on August 8, 2022, Pfizer Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, and Global Blood Therapeutics, Inc., a U.S.-based Healthcare company, announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer Inc will acquire all the outstanding shares of Global Blood Therapeutics, Inc. for US$ 68.50 per share in cash, for a total enterprise value of approximately US$ 5.4 billion, including debt and net of cash acquired. The Boards of Directors of both companies have unanimously approved the transaction.

Key features of the study:

• This report provides an in-depth analysis of the global hemoglobinopathy treatment drugs market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hemoglobinopathy treatment drugs market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Baxter International Inc., Prolong Pharmaceuticals, Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
• Global hemoglobinopathy treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemoglobinopathy treatment drugs market

Detailed Segmentation:

• Global Hemoglobinopathy Treatment Drugs Market, By Drug Type:
  • Analgesics
  • Antibiotics
  • ACE Inhibitors
  • Hydroxyurea
  • Others
• Global Hemoglobinopathy Treatment Drugs Market, By Disease Type:
  • Thalassemia
  • Sickle Cell Disease
  • Other Hb Variants Diseases
• Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Hemoglobinopathy Treatment Drugs Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Europe
    
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
  • Middle East
    
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Bristol-Myers Squibb Company
  • GlycoMimetics Inc.
  • Pfizer Inc.
  • Anthera Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Mast Therapeutics
  • Daiichi Sankyo Company Ltd.
  • Novartis International AG
  • Bluebird Bio Inc.
  • HemaQuest Pharmaceuticals Inc.
  • Emmaus Medical Inc.
  • Baxter International Inc.
  • Prolong Pharmaceuticals
  • Medunik USA Inc.
  • Sangamo Therapeutics, Inc.
  • Global Blood Therapeutics, Inc.
  • Alnylam Pharmaceuticals
  • Acceleron Pharma, Inc.